share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K：重大事件
美股sec公告 ·  05/01 16:34
Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc., a specialty pharmaceutical company, has entered into material definitive agreements with certain investors for the immediate cash exercise of outstanding warrants, resulting in approximately $4.4 million in gross proceeds. The agreements involve the exercise of warrants originally issued in October 2022, November 2023, and January 2024 at a reduced price of $6.20 per share. In conjunction with this exercise, Avenue will issue new Series C and D Common Stock purchase warrants. The closing of these transactions occurred on May 1, 2024. H.C. Wainwright & Co., LLC served as the exclusive agent for the transactions, receiving a cash fee, reimbursement of expenses, and issuance of placement agent warrants with an exercise price of $7.75 per share. The company plans to use the net proceeds for general corporate purposes and has committed to filing a registration statement for the resale of the new warrant shares. Additionally, Avenue has agreed not to issue or enter into agreements for a Variable Rate Transaction for twelve months post-closing, with certain exceptions.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, has entered into material definitive agreements with certain investors for the immediate cash exercise of outstanding warrants, resulting in approximately $4.4 million in gross proceeds. The agreements involve the exercise of warrants originally issued in October 2022, November 2023, and January 2024 at a reduced price of $6.20 per share. In conjunction with this exercise, Avenue will issue new Series C and D Common Stock purchase warrants. The closing of these transactions occurred on May 1, 2024. H.C. Wainwright & Co., LLC served as the exclusive agent for the transactions, receiving a cash fee, reimbursement of expenses, and issuance of placement agent warrants with an exercise price of $7.75 per share. The company plans to use the net proceeds for general corporate purposes and has committed to filing a registration statement for the resale of the new warrant shares. Additionally, Avenue has agreed not to issue or enter into agreements for a Variable Rate Transaction for twelve months post-closing, with certain exceptions.
专业制药公司Avenue Therapeutics, Inc. 已与某些投资者签订了实质性的最终协议，以立即兑现未偿还的认股权证，总收益约为440万美元。这些协议涉及行使最初于2022年10月、2023年11月和2024年1月发行的认股权证，降价为每股6.20美元。与此同时，Avenue将发行新的C系列和D系列普通股购买权证。这些交易于2024年5月1日结束。H.C. Wainwright & Co., LLC是这些交易的独家代理人，收取现金费、费用报销，并发行行使价为每股7.75美元的配售代理认股权证。该公司计划将净收益用于一般公司用途，并承诺为转售新认股权证提交注册声明。此外，Avenue已同意在收盘后的十二个月内不发行或签订浮动利率交易协议，但有某些例外情况。
专业制药公司Avenue Therapeutics, Inc. 已与某些投资者签订了实质性的最终协议，以立即兑现未偿还的认股权证，总收益约为440万美元。这些协议涉及行使最初于2022年10月、2023年11月和2024年1月发行的认股权证，降价为每股6.20美元。与此同时，Avenue将发行新的C系列和D系列普通股购买权证。这些交易于2024年5月1日结束。H.C. Wainwright & Co., LLC是这些交易的独家代理人，收取现金费、费用报销，并发行行使价为每股7.75美元的配售代理认股权证。该公司计划将净收益用于一般公司用途，并承诺为转售新认股权证提交注册声明。此外，Avenue已同意在收盘后的十二个月内不发行或签订浮动利率交易协议，但有某些例外情况。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息